Farxiga Significantly Reduced Hospitalization For Heart Failure Or Cv Death In A Broad Patient Population With Type 2 Diabetes In The Landmark Declaretimi 58 Trial | Latest News RSS feed

Farxiga Significantly Reduced Hospitalization For Heart Failure Or Cv Death In A Broad Patient Population With Type 2 Diabetes In The Landmark Declaretimi 58 Trial - Latest News


FARXIGA Significantly Reduced Hospitalization for Heart Failure or CV Death in a Broad Patient Population with Type 2 Diabetes in the Landmark DECLARE-TIMI 58 Trial

--(BUSINESS WIRE)--AstraZeneca today announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial ... showed that FARXIGA significantly reduced the risk of hospitalizati... read more

AstraZeneca PLC (AZN.L)

The biggest clinical trial ... class of diabetes pills shows that AstraZeneca's Farxiga can prevent heart failure and cut the risk of kidney problems in a broad range of patients. Diabetics are at inc... read more

AstraZeneca PLC Price:

The price of one share of stock, which is set by buyers and sellers in the market. Share price can be used to find a company's total market value, as represented by market capitalization. Prices of a ... read more

Looking for another news?


AstraZeneca PLC PE Ratio (Annual)

The price to earnings ratio (PE Ratio) is the measure of the share price relative to the annual net income earned by the firm per share. PE ratio shows current investor demand for a company share. A h... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us